<div style="margin-bottom: 12px;">
    <a href="https://www.upi.com/Health_News/2024/08/26/FDA-approves-Omnipod-Type-2-diabetes/7971724712188/" style="color: black; font-weight: bold;">FDA approves first automated insulin delivery system for people with Type 2 diabetes</a><br/>
    <span style="margin-bottom: 8px">The Food and Drug Administration on Monday approved Insulet's Omnipod 5 automated insulin delivery system for people with Type 2 diabetes.</span>
</div>
<div style="margin-bottom: 12px;">
    <a href="https://www.msn.com/en-us/health/other/almost-half-of-fda-approved-ai-medical-devices-are-not-trained-on-real-patient-data-research-reveals/ar-AA1prYOp" style="color: black; font-weight: bold;">Almost half of FDA-approved AI medical devices are not trained on real patient data, research reveals</a><br/>
    <span style="margin-bottom: 8px">Artificial intelligence (AI) has practically limitless applications in health care, ranging from auto-drafting patient messages in MyChart to optimizing organ transplantation and improving tumor removal accuracy. Despite their potential benefit to doctors and patients alike, these tools have been met with skepticism because of patient privacy concerns, the possibility of bias, and device accuracy.</span>
</div>
<div style="margin-bottom: 12px;">
    <a href="https://www.pharmexec.com/view/fda-approves-arthroscopic-delivery-vericel-maci-knee-cartilage-defects" style="color: black; font-weight: bold;">FDA Approves Arthroscopic Delivery of Vericel’s MACI for Knee Cartilage Defects</a><br/>
    <span style="margin-bottom: 8px">The FDA has approved Vericel Corporation’s MACI for repairing cartilage defects in the knee. According to the company, MACI uses a patient’s own cells cultured on a porcine collagen membrane.</span>
</div>
<div style="margin-bottom: 12px;">
    <a href="https://www.fiercepharma.com/pharma/after-fda-rejection-regeneron-gains-nod-europe-t-cell-engager-odronextamab" style="color: black; font-weight: bold;">After FDA rejection, Regeneron gains nod in Europe for T-cell engager odronextamab</a><br/>
    <span style="margin-bottom: 8px">Five months after the FDA rejected Regeneron’s bid for accelerated approval of its T-cell engager odronextamab because of the immaturity of its confirmatory trial, the European Union has signed off on the treatment for two types of blood cancers.</span>
</div>
<div style="margin-bottom: 12px;">
    <a href="https://www.yahoo.com/news/tattoo-pigments-could-cause-rashes-165553011.html" style="color: black; font-weight: bold;">Tattoo pigments that could cause rashes, lesions recalled: FDA</a><br/>
    <span style="margin-bottom: 8px">A trio of water-based tattoo pigments are being recalled after tests found the bottles present health concerns to consumers, the U.S. Food and Drug Administration (FDA) announced Monday.</span>
</div>
<div style="margin-bottom: 12px;">
    <a href="https://markets.businessinsider.com/news/stocks/rhythm-pharma-fda-to-review-supplemental-new-drug-application-for-imcivree-quick-facts-1033721801" style="color: black; font-weight: bold;">Rhythm Pharma: FDA To Review Supplemental New Drug Application For IMCIVREE - Quick Facts</a><br/>
    <span style="margin-bottom: 8px">Rhythm Pharmaceuticals (RYTM) announced the FDA has accepted the company's supplemental New Drug Application for IMCIVREE, a melanocortin-4 receptor agonist, for the treatment of obesity due to Bardet-Biedl syndrome or pro-opiomelanocortin, including proprotein convertase subtilisin/kexin type 1, or leptin receptor deficiency obesity in children as young as 2 years old. The FDA has granted Priority Review of the sNDA and assigned a PDUFA goal date of December 26, 2024.</span>
</div>
<div style="margin-bottom: 12px;">
    <a href="https://www.psychiatryadvisor.com/news/fda-approves-zurnai-for-emergency-treatment-of-opioid-overdose/" style="color: black; font-weight: bold;">FDA Approves Zurnai for Emergency Treatment of Opioid Overdose</a><br/>
    <span style="margin-bottom: 8px">The Food and Drug Administration (FDA) has approved Zurnai™, the first nalmefene HCl autoinjector for the emergency treatment of known or suspected opioid overdose in adults and pediatric patients aged 12 years and older.</span>
</div>
<div style="margin-bottom: 12px;">
    <a href="https://www.msn.com/en-us/health/other/opinion-fda-s-mdma-rejection-delays-ptsd-treatment-options/ar-AA1psLyT" style="color: black; font-weight: bold;">Opinion: FDA’s MDMA rejection delays PTSD treatment options</a><br/>
    <span style="margin-bottom: 8px">The Food and Drug Administration’s (FDA) recent rejection of midomafetamine (MDMA), along with mental health therapy, for the treatment of post-traumatic stress disorder (PTSD) came as no surprise. Lykos Therapeutics, formerly MAPS, has come under attack for missing safety data, therapist misconduct and a culture of psychedelic evangelism.</span>
</div>
